Skip to search formSkip to main contentSkip to account menu

PTC299

Known as: VEGF Inhibitor PTC299 
An orally bioavailable, small molecule inhibitor of vascular endothelial growth factor (VEGF) synthesis with potential antiangiogenesis and… 
National Institutes of Health

Related topics

Related topics

2 relations
NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Synergistic Effect of DHODH Inhibitor PTC299 with DNA Demethylating Agent Decitabine in Myelodysplastic Syndromes
Background:Myelodysplastic Syndrome (MDS) is a clonal bone marrow disorder characterized by ineffective and clonal hematopoiesis… 
2017
2017
PTC299 Is a Novel DHODH Inhibitor That Modulates VEGFA mRNA Translation and Inhibits Proliferation of a Broad Range of Leukemia Cells
PTC299 was identified in a phenotypic high through put screen as an inhibitor of VEGFA mRNA translation and had been in clinical… 
2012
2012
Circulating VEGF levels as a biomarker to clinical benefit to PTC299, the first inhibitor of VEGF synthesis.
e13588 Background: Solid tumor growth is dependent on angiogenesis, a process mediated primarily by vascular endothelial growth… 
Review
2011
Review
2011
The molecular biology and novel treatments of vestibular schwannomas.
Vestibular schwannomas are histopathologically benign tumors arising from the Schwann cell sheath surrounding the vestibular… 
2011
2011
Results of a study of the oral inhibitor PTC299 on tumor VEGF synthesis.
3069 Background: Antiangiogenic drugs interfere with the VEGF signaling pathway. PTC299, an oral investigational drug, is… 
2011
2011
Reduction of serum VEGF and IL-6 levels in patients with metastatic breast cancer: Results of a study of PTC299, an oral inhibitor of tumor VEGF synthesis, and aromatase inhibitors.
1100 Background: PTC299, an oral investigational drug, suppresses tumor growth by selective posttranscriptional inhibition of… 
2010
2010
The novel antiangiogenic, PTC299, as a treatment for women with metastatic breast cancer.
e13537 Background: PTC299 is a novel oral investigational drug designed to inhibit tumor expression of VEGF and other angiogenic… 
2010
2010
Phase Ib study of PTC299, a novel oral inhibitor of tumor VEGF expression, in patients with advanced cancer.
3041 Background: PTC299 is a novel, oral investigational drug designed to inhibit tumor expression of VEGF and other angiogenic… 
2009
2009
PTC299, a Novel Regulator of Tumor VEGF Expression, Is Well Tolerated and Achieves Target Plasma Concentrations: Dose-Ranging Results of a Phase 1b Study in Women with Metastatic Breast Cancer.
Background: Current anti-angiogenic drugs interfere with the vascular endothelial growth factor (VEGF) signaling pathway. PTC299… 
2007
2007
Phase 1 studies assessing the safety, PK, and VEGF-modulating effects of PTC299, a novel VEGF expression inhibitor
3562 Background: VEGF expression is regulated posttranscriptionally through the 5’- and 3’- untranslated regions (UTRs) of its… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)